Biotech | October 30, 2023
EnginZyme produces key mRNA vaccine ingredient using biocatalysis
2023 Nobel laureates discovered how pseudouridine could make mRNA suitable for vaccines
2023 Nobel laureates discovered how pseudouridine could make mRNA suitable for vaccines
The companies plan to start a pivotal Phase 3 trial in the coming months
Approval based on DESTINY-Lung02 results where AstraZeneca and Daiichi Sankyo’s Enhertu demonstrated a confirmed objective response rate of 49% and median duration of response of 16.8 months in previously treated patients
In the Phase 3 LIBRETTO-431 study, Retevmo more than doubled progression-free survival (PFS) compared to chemotherapy plus pembrolizumab in patients with advanced or metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC)
The company expects that this development could improve the strength of its application to the FDA for new drug approval
RPG Life Sciences has reported total income of Rs. 155.41 crores during the period ended September 30, 2023
The company has reported total income of Rs. 486.16 crores during the period ended September 30, 2023
The company is confident of addressing all the observations within the stipulated time
Syngene gains access to ERS Genomics' foundational CRISPR/Cas9 patent portfolio, ushering in a new era of technical innovation in India for its global partners
New Molecular biology lab launched, AIIA increased its work scope in form of MoUs
Subscribe To Our Newsletter & Stay Updated
